key: cord-1053987-tz8gc3cz
authors: Crombie, Nicholas; Doughty, Heidi A; Bishop, Jonathan R B; Desai, Amisha; Dixon, Emily F; Hancox, James M; Herbert, Mike J; Leech, Caroline; Lewis, Simon J; Nash, Mark R; Naumann, David N; Slinn, Gemma; Smith, Hazel; Smith, Iain M; Wale, Rebekah K; Wilson, Alastair; Ives, Natalie; Perkins, Gavin D
title: Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial
date: 2022-03-07
journal: Lancet Haematol
DOI: 10.1016/s2352-3026(22)00040-0
sha: 0f79c2b72832eeb7c607904a70b959cd25ebb42e
doc_id: 1053987
cord_uid: tz8gc3cz

BACKGROUND: Time to treatment matters in traumatic haemorrhage but the optimal prehospital use of blood in major trauma remains uncertain. We investigated whether use of packed red blood cells (PRBC) and lyophilised plasma (LyoPlas) was superior to use of 0·9% sodium chloride for improving tissue perfusion and reducing mortality in trauma-related haemorrhagic shock. METHODS: Resuscitation with pre-hospital blood products (RePHILL) is a multicentre, allocation concealed, open-label, parallel group, randomised, controlled, phase 3 trial done in four civilian prehospital critical care services in the UK. Adults (age ≥16 years) with trauma-related haemorrhagic shock and hypotension (defined as systolic blood pressure <90 mm Hg or absence of palpable radial pulse) were assessed for eligibility by prehospital critial care teams. Eligible participants were randomly assigned to receive either up to two units each of PRBC and LyoPlas or up to 1 L of 0·9% sodium chloride administered through the intravenous or intraosseous route. Sealed treatment packs which were identical in external appearance, containing PRBC–LyoPlas or 0·9% sodium chloride were prepared by blood banks and issued to participating sites according to a randomisation schedule prepared by the co-ordinating centre (1:1 ratio, stratified by site). The primary outcome was a composite of episode mortality or impaired lactate clearance, or both, measured in the intention-to-treat population. This study is completed and registered with ISRCTN.com, ISRCTN62326938. FINDINGS: From Nov 29, 2016 to Jan 2, 2021, prehospital critical care teams randomly assigned 432 participants to PRBC–LyoPlas (n=209) or to 0·9% sodium chloride (n=223). Trial recruitment was stopped before it achieved the intended sample size of 490 participants due to disruption caused by the COVID-19 pandemic. The median follow-up was 9 days (IQR 1 to 34) for participants in the PRBC–LyoPlas group and 7 days (0 to 31) for people in the 0·9% sodium chloride group. Participants were mostly white (62%) and male (82%), had a median age of 38 years (IQR 26 to 58), and were mostly involved in a road traffic collision (62%) with severe injuries (median injury severity score 36, IQR 25 to 50). Before randomisation, participants had received on average 430 mL crystalloid fluids and tranexamic acid (90%). The composite primary outcome occurred in 128 (64%) of 199 participants randomly assigned to PRBC–LyoPlas and 136 (65%) of 210 randomly assigned to 0·9% sodium chloride (adjusted risk difference –0·025% [95% CI –9·0 to 9·0], p=0·996). The rates of transfusion-related complications in the first 24 h after ED arrival were similar across treatment groups (PRBC–LyoPlas 11 [7%] of 148 compared with 0·9% sodium chloride nine [7%] of 137, adjusted relative risk 1·05 [95% CI 0·46–2·42]). Serious adverse events included acute respiratory distress syndrome in nine (6%) of 142 patients in the PRBC–LyoPlas group and three (2%) of 130 in 0·9% sodium chloride group, and two other unexpected serious adverse events, one in the PRBC-LyoPlas (cerebral infarct) and one in the 0·9% sodium chloride group (abnormal liver function test). There were no treatment-related deaths. INTERPRETATION: The trial did not show that prehospital PRBC–LyoPlas resuscitation was superior to 0·9% sodium chloride for adult patients with trauma related haemorrhagic shock. Further research is required to identify the characteristics of patients who might benefit from prehospital transfusion and to identify the optimal outcomes for transfusion trials in major trauma. The decision to commit to routine prehospital transfusion will require careful consideration by all stakeholders. FUNDING: National Institute for Health Research Efficacy and Mechanism Evaluation.

The following amendments and/or administrative changes have been made to this protocol since the implementation of the first approved version: 

This trial will test the hypothesis that Pre-Hospital Blood Products (PHBP) resuscitation with up to two units each of packed red blood cells (PRBC) and lyophilised (freeze-dried) plasma (LyoPlas N-w which will be referred to as LyoPlas) will improve tissue perfusion (as measured by lactate clearance) and reduce mortality in trauma participants with haemorrhagic shock compared to the current standard practice of crystalloid resuscitation.

The trial includes an internal pilot phase (25 participants) which will test logistical aspects of the trial and assess feasibility and recruitment.

Intervention Delivery Sites (IDS) and Receiving Hospital Sites (RHS).

Traumatic injury Pre-Hospital Emergency Medical team attend Hypotension Systolic Blood Pressure <90mmHg or absence of palpable radial pulse) believed to be due to traumatic haemorrhage.

Children (known or apparently aged <16 years) Blood administered on-scene, prior to randomisation Traumatic cardiac arrest where a) the arrest occurred prior to arrival of the PHEM team and/ or b) the primary cause is not hypovolaemia Refusal of blood product administration (e.g. known Jehovah's Witness) Pregnancy (known or apparent) Isolated head injury without evidence of external haemorrhage Known prisoners in the custody of HM Prison or Probation services 

Main trial data collection ends at withdrawal, acute care discharge, death or at 30 days follow-up, whichever occurs first. Apart from episode mortality data which will be collected up to discharge from the acute care setting, which may be >30 days.

I Episode mortality refers to mortality between time of injury/ recruitment and up to discharge from the primary receiving facility to non-acute care, i.e. discharge home or to long-term care, to rehabilitation or repatriation to a hospital closer to their normal residence II A participant is considered randomised and entered into the trial when the first intervention box has been opened. of these in a different trauma population -one dominated by blunt mechanisms with a far lower incidence of gunshot wounds.

Meta-analysis of observational studies of in-hospital HR suggests increased survival [14, 15] .

However, the minimal pre-hospital evidence is inconsistent. Consultant-delivered battlefield casualty retrieval (with access to pre-hospital blood products (PHBP) including thawed plasma) was associated with reduced mortality in major, but sub-catastrophic injuries (Injury Severity Score 

With the increasing adoption of PHBP resuscitation for trauma in both the UK and abroad, in both military and civilian settings, it is important to determine whether this intervention is, in fact, effective.

The logistical and financial resources required for the provision of PHBP resuscitation are significant and require dedicated use of valuable universal donor blood components. This trial is an opportunity to establish a robust evidence base for PHBP resuscitation; an opportunity, which may fade if the trend for PHBP continues to the point that equipoise is lost despite a lack of high quality evidence, as is the case for in-hospital HR.

The risks to participants in this trial are considered to be minimal. PHBP resuscitation delivers an equivalent intervention to participants which they would inevitably have received on arrival in hospital. The same single donor derived LyoPlas which will be used in this trial is established in the importation under all modelling conditions, the worst-case scenario is that if all fresh frozen plasma (FFP) requirements for patients born after 01 Jan 1996 were met from German sources, 0.1 clinical cases would result (1.9 log reduction compared to UK sourced plasma) [27] . As the majority of the approximately 245 plasma recipients in this study will have been born prior to 1996 (and would receive UK-sourced plasma in routine clinical practice), the additional risk of vCJD transmission from LyoPlas N-w use is considered to approach zero.

In contrast, massive traumatic haemorrhage leading to profound hypotension (systolic blood pressure (SBP) <90mmHg) is associated with 23% mortality [28, 29] . Any benefit from PHBP is potentially lifesaving.

The assessment and management of risk is detailed in the separate RePHILL Risk Assessment document. An on-going evaluation of risk will continue throughout the trial. The principle objective of this trial is to investigate the clinical effectiveness of PHBP resuscitation compared to the current standard care of restricted crystalloid based resuscitation in participants suffering from major traumatic haemorrhage.

To test the hypotheses that, when compared to standard care, does PHBP resuscitation:

I. Improve blood pressure, heart rate and capillary oxygenation on ED arrival?

Prolong on-scene time?

Reduce pre-hospital fluid requirements?

Reduce in-hospital transfusion requirements?

V.

Reduce trauma-induced coagulopathy?

VI. Preserve platelet function?

VII.

Lead to a greater incidence of transfusion-related complications, particularly acute respiratory distress syndrome?

VIII.

Lead to blood product wastage?

Affect haemoglobin concentration levels on ED arrival?

The first 6 months of the RePHILL trial will constitute an internal pilot to assess and confirm the trial logistics to determine if it is both feasible and practical to carry on and recruit into the trial. The pilot will be run at multiple sites to validate the multi-centre aspects of the trial.

At the end of the pilot phase, the following targets should be met to justify progression to the main trial:

Minimum of 25 participants recruited across at least two active sites;

In participants recruited to the trial intervention arm, at least one unit of PRBC and one unit of LyoPlas delivered to at least 80% of participants before reaching hospital

At least 90% complete data capture Data Monitoring and Ethics Committee (DMEC) reports no safety concerns, which would prohibit continuation to main trial. 

The primary outcome is a composite measure consisting of:

Episode mortality IV Lactate clearance. A failure to achieve lactate clearance ≥ 20% per hour in the first 2 hours after randomisation V

Individual components of the primary outcome All-cause mortality within 3 hours of randomisation 

The Pre-Hospital Emergency Medical (PHEM) team (doctor and/or paramedic) will assess the potential participant's vital signs on-scene and confirm that they are eligible to be entered into the RePHILL trial. In all cases, the PI for Intervention Delivery Sites (IDS) will be a medically qualified doctor and they will be responsible for maintaining oversight of the confirmation of eligibility process. Contact with trial participants and/or their relatives/friends to initiate the consent process will be made as soon as practically possible after the initial emergency has passed, taking the utmost care and sensitivity in doing so. Based on findings from previous trauma research studies and from engaging with patient and public representatives it has been suggested that the earliest practicable time to make contact is once the participant is no longer critically ill.

Details of the informed consent discussions will be recorded in the participant's medical notes. This will include date of discussion, the name of the trial, summary of discussion, version number of the participant information sheet (PIS) given to the participant or their legal representative, version number of the informed consent form (ICF) , what type of consent was received (legal representative and/or participant), and that the ICF was signed and dated.

Throughout the follow-up period, the participant's willingness to continue in the trial will be ascertained (through the participant themselves, or their legal representative as appropriate) and

documented in the medical notes, and the participant or legal representative will have the opportunity to ask questions about the trial. Any new information that may be relevant to the participant's continued participation will be provided. Where new information becomes available which may affect the decision to continue, participants or their legal representative will be given time to consider and if happy to continue will be re-consented. Re-consent will be documented in the medical notes. The participant's right to withdraw from the trial will remain. Electronic copies of the PIS and ICF will be available from the Trial Office and will be presented on the headed paper of the local institution. With the participant's prior consent, their General Practitioner (GP) will also be informed that they are taking part in the trial.

The local research team at the receiving hospital will assess if the participant has capacity to consent for themselves. If the participant does have capacity, they will be provided with the Research Ethics Committee (REC) approved PIS explaining the trial and the options of their continued involvement.

The participant will be given time to consider all of the information, have the opportunity to ask questions and discuss with others. A member of the local research team will ask the participant when they would like someone to come back to discuss participation further and potentially receive consent.

The participant may decide that it is not an appropriate time to discuss the trial or they may decide upfront that they do not want to be involved in which case, their feelings will be respected and their decision about continuing in the trial will be recorded.

Consent from a legal representative will be sought as soon as practically possible; with the recommendation being that this is obtained within the first 72 hours of the participant's hospital admission.

In the first instance, the local research team will work to identify a personal legal representative as defined below:

A personal legal representative is a person independent of the trial, who by virtue of their relationship with the trial participant is suitable to act as their legal representative for the purposes of the trial and who is available and willing to act for those purposes.

The personal legal representative will be approached and will be provided with the REC approved personal legal representative information sheet explaining the trial and the options for the participant's continuing involvement, including the need for them to give consent on behalf of the participant. The personal legal representative will then have time to consider the information provided, after which, a member of the local research team will ask when the personal legal representative would like them to come back and discuss participation further and potentially receive consent.

The personal legal representative may decide that it is not an appropriate time to discuss the trial or they may decide that the participant would not want to take part, in which case their feelings will be respected and their decision about the participant continuing in the trial will be recorded. In the event that a personal legal representative cannot be identified, or it is deemed inappropriate to approach the potential personal legal representative, the local research team will work to identify a professional legal representative as defined below:

A person independent of the trial, who is the doctor primarily responsible for the medical treatment provided to that adult. Or a person nominated by the relevant healthcare provider.

Informed consent given by a professional representative shall represent the participant's presumed will.

If the participant does regain capacity during the follow-up period, they will be asked to give consent for themselves using the process outlined in Section 5.1.

The participant's wishes (consent or refusal) will supersede the personal or professional legal representative consent.

Children who are known or apparently aged <16 years are excluded from participating in the RePHILL Trial. However it is recognised that there may be scenarios where participants under the age of 16 are inadvertently randomised e.g., where they appear older than 16 years and do not have identification with them that confirms their actual age. In this scenario, consent will be sought, after the trial intervention, from a parent or guardian. If the participant has capacity, they will also be asked to provide assent for their continued participation in the trial. A Parent/ Guardian Consent Form and an Assent Form (for participants <16 years) will be provided for this purpose.

The most challenging ethical consideration in this trial relates to the inevitable death of some participants. Actively seeking out and informing relatives of trial participation is transparent and avoids potential distress were the family to discover at some future point that their relative had been involved in a research trial. However, informing the family of trial participation in the immediate aftermath of their relative's death will impose an additional emotional burden at a time of great distress. Previous and ongoing emergency care studies have used passive information approaches, placing information in publically accessible locations and in sites likely to be visited by relatives of the deceased (hospitals, GP surgeries, the offices of the Registrars of Births and Deaths). Such information contains brief details of the trial and contact details for those wishing to seek further information about the trial. This allows a relative to make an individual decision as to whether to seek further information as to whether their relative was part of the trial, at a time of their choosing. This is the approach that we will take with the RePHILL trial and a REC approved poster will be placed in appropriate locations of the receiving hospitals. For those participants that have been randomised, but subsequently die at scene, it will be impossible to obtain any form of consent. The data transferred to the BCTU for these participants will be pseudoanonymised with the trial number (this will be obtained when the RePHILL PHEM Case Report Form (CRF) has been completed) and if available, a partial date of birth. An Exit Form will also be completed for these participants, documenting partial date of death.

Should a participant die en route to hospital, the participant's transfer will follow part of the PHEM team's routine process. In these situations, the PHEM team will be responsible for enrolling the patient and completing the RePHILL PHEM CRF and Exit Form. The data that are transferred to BCTU for these participants will also be pseudoanonymised with the trial number and if available, a partial date of birth.

There may be some situations where due to the geographical location of the participant or the severity of their injuries, that the PHEM team will transfer participants to non-RePHILL hospitals.

This may mean that participants are taken to non-RePHILL hospital temporarily, to be stabilised before being transferred to a RePHILL hospital. It could also mean that the participant remains at a non-RePHILL hospital permanently for follow-up or end-of-life care (if further treatment is considered futile). As the RePHILL trial only collects a pseudoanonymised, minimal dataset that is part of the participant's standard of care pathway, the RePHILL Trial Office shall engage with non-RePHILL hospitals to request participant data, the details of which are outlined below:

If the participant is initially stabilised at a non-RePHILL hospital but is then subsequently transferred to a RePHILL hospital, the RePHILL Trial Office will request the following:

o If consent is obtained at the RePHILL hospital, data collected at the non-RePHILL hospital, which relate to the RePHILL trial, will be requested.

o If there is no consent in place, a minimal data set will be requested via the ED 6 Randomisation and Enrolment Process

Randomisation will be provided by a computer generated programme at the Birmingham Clinical Trials Unit (BCTU). Participants will be randomised at the level of the individual in a 1:1 ratio to either PHBP resuscitation or crystalloid resuscitation. The randomisation procedure will be stratified by IDS to account for variation in trauma care and type of trauma between delivery sites.

The role of the blood bank in the RePHILL trial will be to maintain a constant supply of randomised trial interventions to the PHEM team. The blood bank will obtain the randomised allocations via a secure online system (available at: https://www.trials.bham.ac.uk/RePHILL) at the BCTU. Unique log-in usernames and passwords will be provided to the blood bank staff supporting the trial. The online system will be available 24 hours a day, 7 days a week apart from short periods of scheduled maintenance. Alternatively, a back-up telephone toll-free allocation service on 0800 953 0274 is available Monday -Friday, 09:00-17:00. This excludes bank holidays and University of Birmingham closed days. If an online connection is not available, telephone allocation and a back-up paper allocation using a simple randomisation list will be used.

Blood banks will be supplied with pre-printed 'treatment box number' labels. A registered user at the blood bank will request a treatment allocation from the BCTU and will receive a treatment box number and treatment arm allocation. The allocated trial intervention will be packed into transport boxes affixing the correct labels. Transport boxes will be issued as a pair, one marked red and one marked yellow per single randomised allocation. The treatment box number should be identical on each coloured box pair carried. The date and time of expiry will also be written on each transport box.

The packed, sealed transport boxes will be dispatched to the PHEM base using an established courier service as required.

Upon receiving the box pairs from the blood bank, the PHEM team will need to access the RePHILL online system (https://www.trials.bham.ac.uk/RePHILL) and acknowledge receipt. As part of this process, the PHEM team will need to confirm that the boxes are matched, i.e. that they have the same number on both of them, that they are sealed and the time they were received.

During their shift, the PHEM team should ensure that they are carrying a pair of sealed, red and yellow transport boxes with matched box numbers. Where possible, unopened transport boxes (with the seal still intact) should be returned to the blood banks prior to expiry, to minimise wastage. PRBC may be returned to stock and re-issued if there have been no temperature excursions.

The PHEM doctor will assess the potential participant's vital signs on scene and confirm if eligible for entry into the RePHILL trial. If they fulfil the eligibility criteria (as defined in Section 4 of the protocol) then the randomised treatment will be given. Participants are considered randomised into the trial when the PHEM team open the first transport box containing the allocated trial intervention. Eligibility will be documented at the Receiving Hospital Site (RHS) and the RePHILL PHEM Case Report Form (CRF) completed at handover in the ED. To receive a Trial Number, a member of the research team will access the online system at the BCTU and enter the information recorded on the PHEM CRF (Section 6.3).

Delegated site staff can enrol a participant (and obtain a trial number) by accessing the secure online system: https://www.trials.bham.ac.uk/RePHILL. In order to enrol a participant, site staff must have access to the completed 'Eligibility Checklist' and the 'Pre-Hospital Details' sections in the PHEM CRF. All fields must have been completed in order for the participant to be enrolled and a trial number issued.

Due to the emergency nature of this trial, it is highly unlikely that those randomising and enrolling participants to RePHILL will be aware if a participant is already enrolled in a clinical trial. Where a participant is enrolled in RePHILL and is subsequently found to have been participating in a concurrent trial, BCTU will inform the RePHILL CI, who will in turn liaise with the CI for the other trial.

When it is possible to plan in advance, the Trial Management Group (TMG) will consider requests for co-enrolment into other trials in accordance with best practice recommendations [32]. This will ensure careful consideration of participant burden, compatibility of interventions, organisational issues and follow-up. A log of co-enrolled participants will be maintained by BCTU.

Participants who are later found to be ineligible, but who have received the trial intervention will remain in the trial as per protocol and be included in the analysis. For participants who have withdrawn consent for continuing in the trial, data already collected up until the point of withdrawal will be retained and included in the analysis.

The attending PHEM team (doctor and/or paramedic) will assess eligibility on-scene. Prior to delivery of the intervention, eligible participants will have a capillary blood test taken to measure lactate concentration using a point-of-care lactate device. The capillary blood will be obtained by a finger prick on a test strip, no sample can be retained from this, and therefore no tissue will be stored as a result of this test.

The allocated intervention will then be administered as either:

Consisting of up to 4 x 250 mL bags of 0.9% sodium chloride (normal saline). These will be administered as boluses of 250 mL to restore and maintain a systolic blood pressure (SBP) of ≥ 90 mmHg or a palpable radial pulse.

Consisting of up to 2 units of PRBC and 2 units of LyoPlas. These will be administered sequentially.

( 

In both arms of the trial: If hypotension is corrected after the administration of a bolus, no further fluid will be administered. If clinically significant hypotension persists, or reoccurs further boluses will be administered until it is corrected. In each case, a maximum of 4 boluses can be administered as part of the trial interventions.

Any additional fluid boluses required to maintain blood pressure after administration of the 4 trial boluses should be given according to standard local practice.

In cases where the participant is still on scene 2 hours after randomisation, a second capillary blood test should be taken to measure lactate concentration using a point-of-care lactate device at 2 hours after randomisation.

Trial data collected by the PHEM team will be shared with the RHS, in accordance with local policy and recorded on the RePHILL PHEM CRF.

The following will be measured:

Heart rate measured in beats per minute (bpm)

Respiratory rate is the number of breaths (inhalation -exhalation cycles) counted in one minute Capillary oxygen saturation (SpO2) measured by application of a probe to a finger, toe or ear.

SpO2 is the percentage of haemoglobin that is oxygenated

When possible, Near-infra-red spectroscopy (NIRS) will be used to monitor tissue oxygenation and perfusion via a non-invasive adhesive pad attached to the participant's skin.

Lactate concentration will be measured on arrival at ED and 2 hours after arrival as part of standard care. It will also be measured 2 hours after randomisation (if not previously done on scene), for trial purposes. Where possible, a venous sample should be taken, however if this is not possible then an arterial sample is permitted. Lactate concentration will be measured on a near-patient blood gas analyser. There is no processing required before analysis. This is drawn as a normal part of trauma care (i.e. is no extra burden for the participant). The blood volume drawn varies between syringes but is typically between 1 mL and 3 mL, to be drawn into a pre-heparinised syringe.

Lactate clearance[33] is expressed as a percentage per hour (%/h) and is calculated from the measurement of (venous) lactate concentration (with automated analysers that are near-patient) by the PHEM team immediately prior to randomisation (Lac0) and at 2 hours after randomisation (Lach) as:

Routine laboratory testing to include standard care blood tests (including but not limited to, coagulation and transfusion). Transfusion testing to include ABO and RhD group with assessment for mixed field group and antibody screen.

Coagulation will be measured viscoelastically by rotational thromboelastometery (ROTEM ® ):

For sites using the ROTEM ® machine, 4.5 mL of venous blood is to be drawn into a citrated container (BD Vacutainer 367691 or equivalent). The citrated container contains the additive sodium citrate, which inhibits blood clotting. This is a standard tube for blood clotting tests.

No pre-processing is required.

EXTEM and FIBTEM tests will be performed.

Selected sites will have a platelet function analyser ( 

The following assessments are to be made during the hospital admission as indicated by the participant's clinical condition, up to withdrawal, acute care discharge, death or day 30, whichever is earlier.

This will be assessed at day 7. The Berlin definition of ARDS will be used for assessing participants [34] . Criteria for the diagnosis are shown in Table 1 . 

The extent of a participant's organ dysfunction will be recorded using the SOFA score [31] . The score is based on six components, one each for the following systems:

Neurological Cardiovascular Liver Coagulation

The scores are assigned as shown in Tables 2 a-f.

The SOFA score will be determined daily for the duration of intensive care stay up to day 30.

Scores will be derived from routine clinical and laboratory records. 

Refer to Table 3 below: Capillary lactate concentrations taken on-scene will be measured using a simple point-of-care tester. PRBC are a concentrated preparation of red blood cells that is obtained from whole blood by removing the plasma (as by centrifugation).

The PRBC used in RePHILL will be blood group O, RhD negative, Kell negative from NHS Blood and Transplant national stocks supplied by the blood banks that are supporting this trial.

The crystalloid resuscitation comparator arm will consist of 0.9% sodium chloride (normal saline; a solution of sodium chloride in water). This is classified as the comparator IMP in the RePHILL trial.

The trial stock of LyoPlas will be shipped from the central IMP distribution centre to local receiving site pharmacies. One packaged unit of LyoPlas will comprise:

1 glass bottle of 200 mL freeze dried human plasma 1 plastic bag containing 200 mL water for injection 1 transfer set

The PRBC will be from national stocks supplied by the blood banks that are supporting the RePHILL trial.

Normal saline will be from routine NHS stock and does not require any special storage conditions. Normal saline: Will be provided from local site pharmacies as standard NHS stock and will be labelled by site pharmacies prior to transfer to blood banks.

Both IMPs will be labelled in compliance with the applicable regulatory requirements.

LyoPlas is stable between 2 o C -25 o C and should be maintained within these limits whilst stored in local pharmacies and blood banks..

For the RePHILL trial, once packaged into the trial intervention transport boxes, the LyoPlas should be maintained between 15 o C and 25 o C to permit ease of preparation and administration.

PRBC is to be maintained at 4 o C (± 2 o C) in accordance with blood bank standard procedures.

Normal saline should be stored in accordance with the Summary of Product Characteristics (SmPC).

With respect to the interventions:

LyoPlas may be administered via either an intravenous (IV) or intraosseous (IO) route after reconstitution in water, in accordance with the manufacturer's instructions.

Normal saline may be administered via either an intravenous (IV) or intraosseous (IO) route, according to standard clinical practice Fluid boluses should be administered according to standard practice which will usually require that they are delivered through a fluid warmer.

LyoPlas and PRBC have been prepared with citrate, therefore solutions containing calcium must not be administered concurrently through the same line. Medicinal products should not be added to LyoPlas or PRBC. If an acute transfusion reaction (ATR), including allergic reactions, is suspected following IV/IO infusion of either PRBC or LyoPlas, the transfusion should be stopped immediately.

The IV/IO cannula should be retained and the transfusion reaction managed as per standard clinical practice. Table 4a and categorisation of causality shown in Table 4b . 

Adverse Reaction (AR) Any untoward and unintended response in a subject to an investigational medicinal product which is related (or for which a causal relationship cannot be ruled out) to any dose administered to that subject

An adverse reaction the nature and severity of which is not consistent with the information about the medicinal product in question set out: (a) in the case of a product with a marketing authorisation, in the summary of product characteristics for that product; (b) in the case of any other investigational medicinal product, in the investigator's brochure relating to the trial in question.

Any adverse event, adverse reaction or unexpected adverse reaction, respectively, that: results in death; is life-threatening; requires hospitalisation or prolongation of existing hospitalisation; results in persistent or significant disability or incapacity; or consists of a congenital anomaly or birth defect 

There is evidence to suggest a causal relationship, and the influence of other factors is unlikely Possibly

There is some evidence to suggest a causal relationship (e.g. the event occurred within a reasonable time after administration of the trial medication). However, the influence of other factors may have contributed to the event (e.g. the participant's clinical condition, other concomitant events)

There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a reasonable time after administration of the trial medication). There is another reasonable explanation for the event (e.g. the participant's clinical condition, other concomitant treatments)

There is no evidence of any causal relationship

In the RePHILL trial, the LyoPlas and normal saline are categorised as the IMPs and the pharmacovigilance reporting requirements that will be followed are described in this section of the protocol.

As this is a trial using an intervention that also includes a blood component (PRBC), the statutory arrangements for haemovigilance should also be followed (refer to Section 9.7).

AEs will be recorded in the medical records as per standard clinical practice. Most (S)AE/ARs that occur in this trial, whether they are serious or not, will be 'expected' treatment-related consequences of the trial intervention or trauma related.

RePHILL trial participants are likely to have significant co-morbidities and therefore the frequency of AEs is likely to be high. Most of the AEs occurring in RePHILL, whether serious or not, will therefore be anticipated in the sense that they are recognised and accepted complications/consequences of major trauma.

Investigators will report AEs that meet the definition of an SAE, other than the SAEs listed in Section 9.2.1

The following are regarded as expected SAEs (i.e. are recognised complications/consequences of major trauma) for the purpose of this trial and should not be reported on an SAE Form. These events should be reported on the appropriate trial CRF(s) instead and will not be subject to expedited reporting.

Death ( SAEs that are related to a pre-existing condition are not required to be reported.

Known pregnancy at the time of enrolment is an exclusion criterion for the RePHILL trial, however, should a participant later be found to have been pregnant at the time of trauma and received the trial intervention, the outcome of the pregnancy (spontaneous miscarriage, elective termination, normal birth or congenital abnormality) must be followed-up and documented, even if the participant withdrew consent from follow-up within the trial. Initial notification of pregnancy will be done via a SAE form and the outcome of the pregnancy will be recorded on the Pregnancy Notification Form.

These will be reported to the RePHILL Trial Office.

Details of all SAEs (except those listed as excluded) will be documented and reported from the date of commencement of protocol defined treatment.

Receiving hospitals should report SAE's which are NOT listed as recognised complications of major trauma (as defined in section 9.2.1), to the RePHILL Trial Office on a SAE Form as soon as possible and no later than 24 hours after becoming aware of the event.

Complete SAE Forms should be faxed to the RePHILL Trial Office on: The research team at site will be required to respond to any related queries raised by the RePHILL Trial Office as soon as possible.

Site Investigators should also notify their own institutions of any SAEs in accordance with their institutional policies.

For SAE Forms completed by someone other than the Investigator, the Investigator will be required to countersign the original SAE Form to confirm agreement with the categorisation of seriousness and causality assessments. The SAE Form should then be returned to the RePHILL Trial Office and a copy retained at site.

Participants should be followed up until resolution or stabilisation of the event. Follow-up information should be provided as soon as available.

On receipt of the SAE form, the RePHILL Trial Office will allocate each SAE a unique reference number which will be forwarded to the receiving hospital as proof of receipt. The SAE reference number should be quoted on all correspondence and follow-up reports regarding the SAE.

On receipt of an SAE Form, seriousness and causality will be reviewed independently by the Chief Investigator (CI; or nominated delegate). A SAE judged to have a reasonable causal relationship with the trial intervention will be regarded as a Serious Adverse Reaction (SAR). The causality assessment given by the PI will not be downgraded by the CI "or delegate(s)". If the CI "or delegate(s)" disagrees with the PI's causality assessment, the opinion of both parties will be documented, and where the event requires further reporting, the opinion will be provided with the report.

The CI (or nominated individual) will also assess all SARs for expectedness. If the event meets the definition of a SAR that is unexpected (i.e. is not defined in the approved version of the Reference Safety Information) it will be classified as a Suspected Unexpected Serious Adverse Reaction (SUSAR). 

The RePHILL Trial Office will report a minimal data set of all individual events categorised as a fatal or life threatening SUSAR to the Medicines and Healthcare products Regulatory Agency (MHRA) and REC within 7 days. Detailed follow-up information will be provided within an additional 8 days.

All other events categorised as non-life threatening SUSARs will be reported within 15 days.

A copy will be sent to the Trial Sponsor at the time of sending the SUSAR report.

The RePHILL Trial Office will report details of all SAEs and SARs (including SUSARs) to the MHRA and REC annually from the date of the Clinical Trial Authorisation, in the form of a Development Safety Update Report (DSUR).

A copy will also be sent to the Sponsor at the time of sending out the DSUR.

The MHRA, REC and Sponsor will be notified immediately if a significant safety issue is identified during the course of the trial.

Details of all SUSARs and any other safety issue(s) which arise during the course of the trial will be reported to Principal Investigators (PI). A copy of any such correspondence should be filed in the Investigator Site File (ISF).

Staff at IDS will be responsible for reporting all transfusion-related adverse events via Serious

Directive [35, 36] . Similarly, the receiving hospital staff are also responsible for reporting all transfusion-related adverse events, including acute transfusion reactions (<24 hr) and delayed transfusion reactions (>24 hr), to SHOT/SABRE according to standard procedures.

Each individual blood bank issuing blood will have their own their local policies and procedures for the response to a possible transfusion event and should ensure full compliance with their own licence and MHRA. Where the receiving hospital blood bank is different from the issuing hospital blood bank, then both parties should co-ordinate to ensure traceability and reporting. The hospital blood transfusion laboratory that provided the PRBC (coordinating blood bank) must be informed immediately of all adverse events and reactions. Advice on clinical management and investigation of serious adverse reactions can be obtained from the hospital consultant responsible for blood transfusion at the coordinating blood bank.

The RePHILL Trial Office will provide the MHRA with DSURs. The reports will be submitted within 60 days of the Development International Birth Date (DIBD) of the trial each year until the trial is declared ended.

An Annual Progress Report will be submitted to the REC within 30 days of the anniversary date on which the favourable opinion was given and annually until the trial is declared ended. A copy will also be sent to the Sponsor at the time of sending out the DSUR.

If any urgent safety measures are taken, the CI/BCTU shall immediately, and in any event no later than 3 days from the date the measures are taken, give written notice to the REC and MHRA of the measures taken and the circumstances giving rise to those measures.

In accordance with Regulation 29A of the Medicines for Human Use (Clinical Trials) Regulations 2004 and its amendments, the Sponsor of the trial is responsible for notifying the licensing authority in writing of any serious breach of the conditions and principles of Good Clinical Practice (GCP) in connection with that trial or the protocol relating to that trial, within 7 days of becoming aware of that breach.

For the purposes of this regulation, a "serious breach" is a breach which is likely to effect to a significant degree the safety or physical or mental integrity of the subjects of the trial; or the scientific value of the trial. Sites are therefore requested to notify the RePHILL Trial office of any suspected trial-related serious breach of GCP and/or the trial protocol. Where the RePHILL Trial office is investigating whether or not a serious breach has occurred, sites are also requested to cooperate with the Trial Office in providing sufficient information to report the breach to the MHRA where required and in undertaking any corrective and/or preventive action. Sites may be suspended from further recruitment in the event of serious and persistent non-compliance with the protocol and/or GCP, and/or poor recruitment. The BCTU on behalf of the Sponsor shall notify the MHRA and REC in writing of serious breaches.

All data will be handled in accordance with the current UK recommended data protection regulations.

During the hospital admission, up to withdrawal, discharge from acute care, death or day 30 (whichever is earlier), where possible, outcome data will be extracted from participant's clinical notes and laboratory reports, to complete the RePHILL trial CRFs ( Table 5 ). It is the responsibility of the Investigator to ensure the accuracy of all data entered in the CRFs. The

RePHILL Trial Signature and Delegation Log will identify all those personnel with responsibilities for data collection. The Trial Office must be informed immediately of any change in the site research team.

Prior to commencing recruitment, all sites will undergo a process of initiation and will have completed GCP training. Key members of the site research team will be required to attend either a meeting or a teleconference covering aspects of the trial design, protocol procedures, AE, collection and reporting of data and record keeping. Sites will be provided with an ISF containing essential documentation, instructions, and other documentation required for the conduct of the trial.

The CRFs will comprise, but will not necessarily be limited to those listed in Table 5 .

If paper CRFs are being completed, they must be signed and dated and returned to the RePHILL be crossed out with a single stroke, the correction inserted and the change initialled and dated. If it is not obvious why a change has been made, an explanation should be written next to the change.

Data reported on each CRF should be consistent with the related source data or the discrepancies should be explained. If information is not known, this must be clearly indicated on the CRF. All sections should be completed; all missing and ambiguous data will be queried. In all cases it remains the responsibility of the PI to ensure that the CRF has been completed correctly and that the data are accurate. Paper CRFs received will be entered onto the trial database by a trained member of the BCTU trial team.

If remote electronic data entry is being undertaken then CRFs should be entered online at:

https://www.trials.bham.ac.uk/RePHILL. Authorised staff at IDS and RHS will require an individual secure login username and password to access this online data entry system. As above, data reported should be consistent with the related source data and all missing and erroneous data will be queried.

CRF version numbers may be updated by the RePHILL Trial Office, as appropriate, throughout the duration of the trial. Whilst this will not constitute a protocol amendment, new versions of the CRFs must be implemented by participating sites immediately on receipt.

It will be the responsibility of the PI to ensure the accuracy of all data entered in the CRFs. The

RePHILL Trial Signature and Delegation Log will identify all those personnel with responsibilities for data collection.

Access to data, including the final trial dataset will be limited to the Research Team.

The investigator(s)/ institution(s) will permit trial-related monitoring, audits REC review and regulatory inspection(s), providing direct access to source data/ documents. Trial participants are informed of this during the informed consent discussion and will consent to provide access their medical notes.

Although no definitive data exists on this composite outcome, the observational studies suggest potentially dramatic reductions in mortality from civilian pre-hospital PRBC[21] and military prehospital PRBC with thawed plasma [17] . Following extensive consultation with experts in pre-hospital trauma resuscitation, it is considered that an absolute reduction of 10% in the proportion of participants experiencing one of the component primary outcomes is clinically meaningful for the participants and is an appropriate effect size upon which to base the power calculation. To detect an absolute difference of 10% between groups in the proportion of participants experiencing either episode mortality or lactate clearance <20%/h in the two hours postrandomisation (i.e. from 20% in the standard care group to 10% in the group receiving PHBP) using the method of difference between proportions (2-sided Fisher's Exact Test) with 80% power, and a type 1 error rate of 5% (i.e. α=0.05), requires 219 participants per group to be randomised, 438 participants in total. Assuming and adjusting for a 10% loss to follow-up rate, 490 participants will need to be recruited.

The interim analysis for the DMEC meeting in May 2018 reported the results on the 192 participants recruited by 20 th April 2018. A pooled event rate of 65% experiencing either episode mortality or lactate clearance <20%/h in the two hours post-randomisation was observed in these participants.

This observed rate does not correspond with the pooled event rate of 15% assumed in the original sample size calculations. On the DMECs recommendations, this issue was discussed with the TSC in October 2018, and it was agreed that the power calculations will be framed in terms of relative risk rather than absolute risk but the original target sample size of 490 will not be changed.

Assuming the pooled event rate remains at 65% and allowing for a 10% loss to follow-up rate, 490 participants will provide 80% power to detect a relative risk ratio of 0.82 (i.e. from 71.7% in the standard care group to 58.3% in the group receiving PHBP) using the method of difference between proportions (2-sided Fisher's Exact Test), and a type 1 error rate of 5% (i.e. α=0.05). This estimated relative risk ratio is consistent with the relative risk ratios of 1·54[38] and 0.70 [39] reported in two recent pre-hospital RCTs using plasma in one of the treatment arms.

A separate Statistical Analysis Plan (SAP) will be produced and will provide a more comprehensive description of the planned statistical analyses. A brief outline of these analyses is given below.

The primary comparison groups will be composed of those resuscitated with PHBP versus those resuscitated with normal saline. All analyses will be based on the intention to treat principle, i.e. all participants will be analysed in the groups to which they were allocated irrespective of compliance with the randomised treatment allocation or other protocol violation. For all major outcome measures, summary statistics and differences between groups (e.g. mean differences, relative risks, hazard ratios) will be presented, with 95% confidence intervals and p-values from two-sided tests also given.

The data will be assessed for normality and appropriate data transformations or non-parametric tests will be used if necessary. Outcomes will be adjusted for the minimisation variable, IDS, where possible. A p-value of <0.05 will be considered statistically significant, and no adjustment for multiple comparisons will be made. 

The primary outcome is a composite measure of episode mortality VII and early lactate clearance (see section 7.2.4 for formula for calculating lactate clearance) and is measured as a binary outcome.

Participants clearing less than 20% per hour of their lactate between randomisation and 2 hours after randomisation or dying will be defined as experiencing the primary outcome. A log-binomial regression model, adjusting for IDS, will be used to calculate the relative risk and 95% confidence interval. As this is a composite endpoint, it will also be reported in accordance with the recommendations of Ferreira-González et al [37] .

Dichotomous data (e.g. development of ARDS, mortality at specified time-points) will be analysed in the same way as the primary outcome. Survival data (e.g. mortality) will be analysed using the logrank test with a Cox Proportional Hazard model used to calculate hazard ratios, if the assumptions of proportionality are met. Continuous outcomes (e.g. pre-hospital fluid volume, vital signs) will be analysed at specified time-points using linear regression models, with mean differences and 95% confidence intervals reported.

Eleven a priori subgroup analyses are planned with respect to both the primary and secondary outcome measures. The subgroups will be IDS, mode of transport (air .vs. ground), initial lactate concentration (≤ 2.2 mmol/L .vs. >2.2 mmol/L), time to ED from injury (≤ 1 hour .vs. >1 hour), mode of injury (blunt, penetrating, crush), volume of pre-hospital fluid given (total intervention 4 units) vs.

those not receiving the total intervention), age (<50 years, 50-70 years, >70 years), head injury (positive vs. negative), compressible haemorrhage (compressible haemorrhage vs. noncompressible haemorrhage), pre-morbid drug history (anticoagulant or antiplatelet medication vs. no anticoagulant or antiplatelet medication) and age of blood products (<8 days vs. ≥ 8 days). Tests for statistical heterogeneity (e.g. by including the treatment group by subgroup interaction parameter in the regression model) will be performed prior to any examination of effect estimates within subgroups. The results of subgroups will be treated with caution and will be used for the purposes of hypothesis generation only.

VII Episode mortality refers to mortality between time of injury/ recruitment and discharge from the primary receiving facility to non-acute care, i.e. discharge home or to long-term care, to rehabilitation or repatriation to a hospital closer to their normal residence. 

Every attempt will be made to collect full follow-up data on all study participants, it is thus anticipated that missing data will be minimal. Participants with missing primary outcome data will not be included in the primary analysis in the first instance. This presents a risk of bias, and sensitivity analyses will be undertaken to assess the possible impact of the risk. In brief, missing responses will be simulated using a Markov chain Monte Carlo method (MCMC) to generate multiple datasets. Analysis will be then be performed on each set with the results combined using Rubin's rule to obtain a single set of results (treatment effect estimate and confidence intervals). Any sensitivity analyses will not, irrespective of their differences, supplant the planned primary analyses. Full details will be included in the SAP.

Interim analyses of major outcome measures and safety data will be conducted and provided in strict confidence to the independent DMEC (see section 17.3). Details of the agreed plan will be written in the SAP.

The final analysis for the study will occur once all participants have completed the trial as per the end of trial definition and corresponding outcome data has been entered onto the study database and validated as being ready for analysis.

For participants, the main trial data collection ends at withdrawal, acute care discharge, death, or at 30 days follow-up, whichever occurs first. Apart from episode mortality data which will be collected up to discharge from an acute care setting, which may be >30 days.

The end of trial will be six months after the date of last data capture (to include resolution of missing data and data queries). The RePHILL Trial Office will notify the MHRA and REC that the trial has ended within 90 days of the end of trial. Where the trial has terminated early, the RePHILL Trial

Office will inform the MHRA and REC within 15 days of the end of trial. The RePHILL Trial Office will provide them with a summary of the clinical trial report within 12 months of the end of trial.

A copy of the end of trial notification as well as the summary report will also be sent to the Sponsor at the time of sending these to the MHRA and REC.

All essential documents within the Trial Master File will be archived for up to 25 years after completion of the trial. Electronic data sets will be stored indefinitely. 

The investigator(s)/institution(s) will permit trial-related monitoring, quality checks, audits, REC review, and regulatory inspection(s), providing direct access to source data/documents. The Principal Investigator will comply with these visits and any required follow up. Sites are also requested to notify the RePHILL Trial Office of any MHRA inspections.

Trial participants who regain capacity will be informed of this during the informed consent discussion and will consent to provide access to their clinical notes. Personal or legal representatives will be informed of this during the informed consent discussion where consent is being sought due to lack of participant capacity and will also consent to provide access to the participant's clinical notes for these purposes.

The trial will be performed in accordance with the recommendations guiding physicians in biomedical research involving human subjects, adopted by the 18 th World Medical Association General Before any participants are enrolled into the trial, the Principal Investigator at each site is required to obtain local R&D approval. Sites will not be permitted to enrol participants until written confirmation of R&D approval is received by the Principal Investigator.

It is the responsibility of the Principal Investigator to ensure that all subsequent amendments gain the necessary local approval. This does not affect the individual clinicians' responsibility to take immediate action if thought necessary to protect the health and interest of individual participants. 

Monitoring of RePHILL will ensure compliance with GCP. A risk proportionate approach to the initiation, management and monitoring of RePHILL will be adopted and outlined in the trial-specific risk assessment.

The RePHILL Trial Office will be in regular contact with the site research team to check on progress and address any queries that they may have. The Trial Office will check incoming CRFs for compliance with the protocol, data consistency, missing data and timing. Sites will be asked for missing data or clarification of inconsistencies or discrepancies. Sites will be requested to send in copies of signed ICFs and other documentation for in-house review for all participants giving explicit consent.

Additional on-site monitoring visits may be triggered, for example poor CRF return, poor data quality, excessive number of deviations. This will be detailed in the monitoring plan. If a monitoring visit is required, the RePHILL Trial Office will contact the site to arrange a date for the proposed visit and will provide the site with written confirmation. Investigators will allow the RePHILL trial staff access to source documents as requested.

The TMG will comprise the CI, other lead investigators (clinical and non-clinical) and members of the BCTU. The TMG will be responsible for the day-to-day running and management of RePHILL. It will convene at regular intervals.

The role of the TSC is to provide the overall supervision of the trial. The TSC will monitor trial progress and conduct and advise on scientific credibility. The TSC will consider and act, as appropriate, upon the recommendations of the DMEC. Further details of the remit and role of the TSC are available in the TSC Charter.

An independent DMEC will be established to oversee the safety of participants in the trial. The DMEC will meet prior to the trial opening to enrolment and again once the first 25 participants have been entered into the study or at the end of the 6 month internal pilot trial part, whichever occurs first, to assess the safety data, and advise on continuation to the main phase III trial (see Section 3.2 for the Internal Pilot Stopping Rules). Since this is an internal pilot trial, and this safety data will be included in the main analysis of the RePHILL trial, this data will remain confidential, except to members of the DMEC and the trial statistician(s) performing the analysis.

During the main phase III trial, the DMEC will meet at least annually, or as per a timetable agreed by the DMEC prior to trial commencement. Data analyses will be supplied in confidence to the DMEC, which will be asked to give advice on whether the accumulated data from the trial, together with the results from other relevant research, justifies the continuing recruitment of further participants. The DMEC will operate in accordance with the trial specific charter.

If one treatment really is substantially better or worse than the other with respect to the primary outcome, then this may become apparent before the target recruitment has been reached.

Alternatively, new evidence might emerge from other sources that any one treatment is definitely more, or less, effective than the other. To protect against this, during the main period of recruitment to the trial, interim analyses of the primary outcome and adverse events will be supplied, in strict confidence, to the independent DMEC, along with updates on results of other related studies, and any other analyses that the DMEC may request. The DMEC will advise the chair of the TSC if, in their view, any of the randomised comparisons in the trial have provided both (a) "proof beyond reasonable doubt" VIII that for all, or for some, types of participants one particular treatment is definitely indicated or definitely contraindicated in terms of a net difference in the major endpoints, and (b) evidence that might reasonably be expected to influence the participant management of many clinicians who are already aware of the other main trial results. The TSC can then decide whether to close or modify any part of the trial. Unless this happens, however, the TMG, TSC, the investigators and all of the central administrative staff (except the statisticians who supply the confidential analyses) will remain unaware of the interim results.

The National Institute for Health Research (NIHR) Efficacy & Mechanism Evaluation Programme is funding this trial (project number 14/152/14).

This is a clinician-initiated study. There are no special arrangements to provide compensation for non-negligent harm to participants. The "Clinical Trial Compensation Guidelines" published by the ABPI will not apply.

VIII Appropriate criteria of proof beyond reasonable doubt cannot be specified precisely, but a difference of at least p<0.001 (similar to a Haybittle-Peto stopping boundary) in an interim analysis of a major endpoint may be needed to justify halting, or modifying, the study prematurely. If this criterion were to be adopted, it would have the practical advantage that the exact number of interim analyses would be of little importance, so no fixed schedule is proposed. Participants who sustain injury and wish to make a claim for compensation should do so in writing in the first instance to the organisation where they were treated.

Non-NHS organisations taking part in the study and NHS organisations who are not members of their appropriate national clinical negligence scheme (for example CNST in England, CNORIS in Scotland) must take out adequate insurance, or provide other indemnity satisfactory to the sponsor, to cover their potential liabilities against claims for negligence, and must be able to provide evidence of the cover if requested by the sponsor. The University of Birmingham has in force, a public liability policy and/ or clinical trials policy which provides cover for claims of 'negligent harm' and the activities here are included in that coverage. 

Regular newsletters will keep collaborators informed of trial progress, and regular meetings will be held to report progress of the trial and to address any problems encountered in the conduct of the trial.

The CI will coordinate dissemination of data from RePHILL. All publications and presentations, including abstracts, relating to the main trial will be authorised by the RePHILL TMG. The results of the analysis will be published in the name of the RePHILL Trial Investigators in a peer reviewed journal (provided that this does not conflict with the journal's policy). All contributors to the trial will be listed, with their contribution identified. Trial participants will be sent a summary of the final results of the trial, which will contain a reference to the full paper. All applications from groups wanting to use RePHILL data to undertake original analyses will be submitted to the TMG for consideration before release. To safeguard the scientific integrity of RePHILL, trial data will not be presented in public before the main results are published without the prior consent of the TMG.

Appendix page 54

Appendix page 54

Further Secondary and Exploratory Outcomes that do not appear in the main manuscript are presented in Table 1 . 

Bayesian models were fitted using three different prior distributions: non-informative prior, sceptical prior such that the probability of observing a treatment effect at least as large as the specified relative risk ratio of 0.82 is less than 5%, and informative prior reflecting current knowledge. For each set of the priors, the table below provides summary statistics (the mean value, and upper and lower 2.5% quantiles) of the primary outcome event rates in each treatment group. 

For each set of priors, the median risk ratios and associated 95% higher posterior density intervals for the primary outcome are presented in Table 3 , along with the posterior probabilities that the risk ratio is less than 1, 0.8, and 0.7. For each set of priors, the median absolute risk differences and associated 95% higher posterior density intervals for the primary outcome are presented in Table 4 , along with the posterior probabilities that the absolute risk difference is less than 0, -10%, and -20%. 

For each set of priors, the median risk ratios and associated 95% higher posterior density intervals for Episode Mortality are presented in Table 5 , along with the posterior probabilities that the risk ratio is less than 1, 0.8, and 0.7. For each set of priors, the median absolute risk differences and associated 95% higher posterior density intervals for Episode Mortality are presented in Table 6 , along with the posterior probabilities that the absolute risk difference is less than 0, -10%, and -20%. Bayesian Analysis of Failure to Clear Lactate

For each set of priors, the median risk ratios and associated 95% higher posterior density intervals for Failure to clear lactate are presented in Table 7 , along with the posterior probabilities that the risk ratio is less than 1, 0.8, and 0.7. For each set of priors, the median absolute risk differences and associated 95% higher posterior density intervals for Failure to clear lactate are presented in Table 8 , along with the posterior probabilities that the absolute risk difference is less than 0, -10%, and -20%. 

Sensitivity analyses for the primary outcome are presented in Table 9 . 

The post-hoc subgroup analyses, for the Primary Outcome, of time from scene to arrival at ED (< 20 minutes .vs. ≥ 20 minutes) and injury severity (NISS bands of <16 .vs. 16-30 .vs. >30) are displayed in Figure 1 . 

Plasma transfusion strategies for critically ill patients

Vital signs Heart Rate (bpm) On scene 115 (31)

P=0.13 6 hrs after ED arrival

Systolic Blood Pressure (mmHg) On scene 73

P=0.99 6 hrs after ED arrival

Diastolic Blood Pressure

P=0.46 2 hrs after ED arrival

Oxygen Saturation (%) On scene 92

Laboratory Results Lactate Concentration (mmol/L) 2 hours post-randomisation based on time 382

Cryoprecipitate (bags)

P=0.02 24 hrs after arrival at ED 105

S8 -The RePHILL Collaborative Group

Page 55 of 58

A list of intervention delivery sites and principal investigators are provided in Table 10 . Ridgeplots display the estimated density plots for Haemoglobin concentration on ED arrival by treatment group. Vertical lines within plots denote quartiles. ED = Emergency Department. PRBC = packed red blood cells.

Appendix page 112